TScan Therapeutics, Inc. (TCRX) stock
TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15−0.00 (-1.72%)
Close on Nov 18, 2026Market cap $10.06MP/E –Yield –
TScan Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
TScan Therapeutics's total debt was $32.78M at Jun 30, 2026. For fiscal 2025 it was $32.53M, up 1.4% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.53M | +1.4% |
| FY2024 | Dec 31, 2024 | $32.07M | +6.7% |
| FY2023 | Dec 31, 2023 | $30.05M | +2.6% |
| FY2022 | Dec 31, 2022 | $29.29M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $32.78M | +1.5% |
| Q1 FY2026 | Mar 31, 2026 | $32.65M | +1.5% |
| Q4 FY2025 | Dec 31, 2025 | $32.53M | +1.4% |
| Q3 FY2025 | Sep 30, 2025 | $32.41M | +5.8% |
| Q2 FY2025 | Jun 30, 2025 | $32.30M | +6.1% |
| Q1 FY2025 | Mar 31, 2025 | $32.18M | +6.4% |
| Q4 FY2024 | Dec 31, 2024 | $32.07M | +6.7% |
| Q3 FY2024 | Sep 30, 2024 | $30.65M | +2.3% |
| Q2 FY2024 | Jun 30, 2024 | $30.45M | +2.4% |
| Q1 FY2024 | Mar 31, 2024 | $30.25M | +2.5% |
| Q4 FY2023 | Dec 31, 2023 | $30.05M | +2.6% |
| Q3 FY2023 | Sep 30, 2023 | $29.95M | +3.0% |
| Q2 FY2023 | Jun 30, 2023 | $29.72M | – |
| Q1 FY2023 | Mar 31, 2023 | $29.50M | – |
| Q4 FY2022 | Dec 31, 2022 | $29.29M | – |
| Q3 FY2022 | Sep 30, 2022 | $29.07M | – |
See a number that looks wrong?